A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1
Latest Information Update: 10 Sep 2025
At a glance
- Drugs E-2086 (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
Most Recent Events
- 08 Sep 2025 According to the Eisai Co Ltd Media Release, There were a total of 21 patients in the clinical trial (21 patients received the study medication, 19 patients completed the trial).
- 08 Sep 2025 Results published in the Media Release
- 03 Sep 2025 According to the Eisai Co Ltd Media Release, data from this study will be presented at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10.